Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets
Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study. The company must now show the drug cuts key events such as heart attack, stroke and ...
Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study.
The company must now show the drug cuts key events such as heart attack, stroke and ...
